Latest News

Dual-layer microneedle patch delivers fast itch relief and sustained methotrexate-zinc therapy, improving psoriasis inflammation, immune balance, and infection protection in mice.

The FDA finalized the addition of bemotrizinol to the OTC sunscreen monograph, approving the broad-spectrum UV filter for use at concentrations up to 6% in adults and children 6 months or older.

The priority review pathway cuts the standard 300-day Canadian review timeline to approximately 180 days, reflecting Health Canada's assessment of serious unmet need in the EB population.

In clinical medicine and science, robust often fails because it lacks quantifiable meaning.

AI analysis of 187,016 menopausal women links hair loss severity to thyroid disease, gut symptoms, scalp inflammation, and genetics, supporting broader diagnostic workups beyond hormones.

As Epiduo goes OTC, offering once-daily adapalene+BPO for mild to moderate acne, Heather Woolery-Lloyd, MD, FAAD, gives advice on irritation, purging, and simplifying routines.

The June issue of Dermatology Times highlights the latest advances in skin cancer, psoriasis, atopic dermatitis, hidradenitis suppurativa, and emerging dermatology technologies.

Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.

Can daily supplements "clear skin from within", or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Every week, we cut through the noise to bring clinicians the trial results, approvals, and emerging therapies that are actually moving the needle.

Oral peptide drugs move beyond injections, bringing targeted psoriasis therapy like icotrokinra and reshaping dermatology’s treatment options.

Phase 1/2 data from RESET-Myositis, RESET-SSc, and RESET-SLE presented at EULAR 2026 show durable immunomodulator-free responses and a consistent safety profile across indications.

Medicus Pharma advances microneedle doxorubicin therapy to clear multiple Gorlin syndrome BCC lesions.